Stock Taper
EARNINGS CALL ARCHIVE 4 CALLS ON FILE
ABCL — AbCellera Biologics Inc.
NASDAQ
FULL STOCK PAGE →

Q4 2025 Earnings Call Summary

FEB 24, 2026
REVENUE
$44.9M +400.9%
NET MARGIN
-19.9% +617.9 PTS
EPS
-$0.03 +84.2%
FREE CASH FLOW
-$44.6M +27.5%

No summary has been written for this call yet.